ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy

September 27, 2013

Cancer Epidemiology Hampered By Bureaucratic Delays, Lack of Cooperation, NCI Group Says

September 29, 1978

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

NCI To Recomplete CIDAC Contracts

September 23, 1977

Cuts Claimed to Displace “Millions” of Patients Yet None Seem to Complain. Why Not?

April 25, 2013

PRI, Fending Off More Giants, Reportedly wins New operations. Support contract at Frederick

July 10, 1987